In the current month, PBYI has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PBYI average Analyst price target in the last month is 6.000.
Based on analysts' estimates, PBYI EPS is projected to reach 0.230 in FY2026Q4, following reported EPS of 0.120 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD 0.12, while Puma Biotechnology IncPBYI's earnings per share (EPS) for the previous quarter was USD 0.16. EPS for the next quarter is expected at USD 0.23.